Meeting
2021 ASCO Annual Meeting
Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
Authors
Greg Yothers
NSABP, NRG Oncology and the University of Pittsburgh, Pittsburgh, PA
Greg Yothers , Alan P. Venook , Takeharu Yamanaka , Yan Lin , Michael Crager , Calvin Y. Chao , Frederick L Baehner , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3599)
DOI
10.1200/JCO.2021.39.15_suppl.3599
Abstract #
3599
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Prospective evaluation of a 12-gene assay on treatment recommendations in patients with stage II colon cancer.
First Author: Geetika Srivastava
Poster
2019 Gastrointestinal Cancers Symposium
The effect of adjuvant chemotherapy for stage III colon cancer in elderly patients.
First Author: Naomi Hayashi
Poster
2018 ASCO Annual Meeting
A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).
First Author: Shigeki Yamaguchi
Poster
2018 Gastrointestinal Cancers Symposium
Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study.
First Author: Takeharu Yamanaka